肝细胞癌
接种疫苗
埃利斯波特
颗粒酶B
免疫系统
医学
免疫学
免疫疗法
CD8型
癌症研究
细胞毒性T细胞
肝癌
生物
体外
生物化学
作者
Shih-Feng Yang,Meng–Tzu Weng,Ja-Der Liang,Ling-Ling Chiou,Yu-Chen Hsu,Ying-Te Lee,Shin-Yun Liu,Meng-Chuan Wu,Huei-Chi Chou,Lifang Wang,Shu‐Han Yu,Hsuan-Shu Lee,Jin‐Chuan Sheu
出处
期刊:Cancer Letters
[Elsevier]
日期:2023-06-01
卷期号:563: 216192-216192
被引量:4
标识
DOI:10.1016/j.canlet.2023.216192
摘要
Immune checkpoint inhibitors are groundbreaking resources for cancer therapy. However, only a few patients with hepatocellular carcinoma (HCC) have shown positive responses to anti-PD-1 therapy. Neoantigens are sequence-altered proteins resulting from somatic mutations in cancer. This study identified the neoantigens of Hep-55.1C and Dt81 Hepa1-6 HCCs by comparing their whole exome sequences with those of a normal C57BL/6 mouse liver. Immunogenic long peptides were pooled as peptide vaccines. The vaccination elicited tumor-reactive immune responses in C57BL/6 mice, as demonstrated by IFN-γ ELISPOT and an in vitro killing assay of splenocytes. In the treatment of three mouse HCC models, combined neoantigen vaccination and anti-PD-1 resulted in more significant tumor regression than monotherapies. Flow cytometry of the tumor-infiltrating lymphocytes showed decreased Treg cells and monocytic myeloid-derived suppressor cells, increased CD8+ T cells, enhanced granzyme B expression, and reduced exhaustion-related markers PD-1 and Lag-3 on CD8+ T cells in the combination group. These findings provide a strong rationale for conducting clinical studies of using neoantigen vaccination in combination with anti-PD-1 to treat patients with HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI